Glenmark Expects ‘Strong Year’ With ‘First’ EU Spiriva Rival Imminent
Signed Licensing Deal For Tiotropium Bromide In 2018
Glenmark said it would continue to deliver new respiratory products in Europe moving forward as the Indian firm lines up what it believes will be the first generic version of Boehringer Ingelheim’s Spiriva Handihaler.
You may also be interested in...
Glenmark is toasting another launch for the company’s Ryaltris novel treatment for allergic rhinitis, this time with plans to roll the product out in 17 countries across western Europe.
The FDA has issued 69 product-specific guidances for generic drug development, comprising 26 new guidances and 43 revised documents.
Glenmark is aiming to bolster its burgeoning respiratory presence in Europe by signing an exclusive licensing and marketing agreement with an undisclosed third party for a generic of Boehringer Ingelheim’s Spiriva Handihaler (tiotropium bromide) dry-powder inhaler in Western European markets.